CNR1 and liver dysplastic nodule: However, while INV-202 restored these diabetic and DN markers, it did not restore polyuria or decrease glycemia and body weight, as reported previously in STZ mouse models treated with CB1R antagonists or displaying podocyte-specific genetic deletion of CB1R (19, 36).